Residual Disease-Driven Strategy Following Isatuxumab-Carfilzomib. Lenalidomide-Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma: Primary Endpoints of the Phase 3 MIDAS Trail - Perrot, A (EHA, 2025)
Oral Presentation ID